. 2025 Aug 20;15(11):4367–4410. doi: 10.1007/s13346-025-01947-0

Table 5.

Antibody-conjugated nanogels for brain cancer treatment

Type of polymer used	Antibody conjugated + target receptor	Encapsulated Compound	Size	Surface charge	Outcomes (in vitro)	Outcomes (in vivo)	Reference
PEG-b-PMA	CC49 mAb targeting glycoprotein 72 expressed by tumor cells	-	158.9 nm	-17.0 mV	-	-	[231]
Ferritin	Anti-CD47 antibody against glioblastoma tumor	DOX and oxidized dextran	12 nm	-	-Higher tumor penetration, retention and accumulation in 4T1 cells with Dox@HFn Gel compared with Dox@HFn and free drug	-Higher survival rates in glioblastoma mice with antibody-conjugated Dox@HFn Gel (50 days) compared with the control group (34 days) -Higher median survival with Dox@HFn gel and anti-CD47 antibodies compared with control surgery group (50 vs. 34 days)	[232]

Type of polymer used

Antibody conjugated + target receptor

Encapsulated Compound

Size

Surface charge

Outcomes (in vitro)

Outcomes (in vivo)

Reference

PEG-b-PMA

CC49 mAb targeting glycoprotein 72 expressed by tumor cells

158.9 nm

-17.0 mV

Ferritin

Anti-CD47 antibody against glioblastoma tumor

DOX and oxidized dextran

12 nm

-Higher tumor penetration, retention and accumulation in 4T1 cells with Dox@HFn Gel compared with Dox@HFn and free drug

-Higher survival rates in glioblastoma mice with antibody-conjugated Dox@HFn Gel (50 days) compared with the control group (34 days)

-Higher median survival with Dox@HFn gel and anti-CD47 antibodies compared with control surgery group (50 vs. 34 days)